627.8000 -2.05 (-0.33%)
NSE Dec 26, 2025 12:45 PM
Volume: 121.8K
 

Axis Direct
We believe KIMS has a structural growth story (strong ROCE of 32%). It is also a zero net-debt company due to its strong operating cash flow generation. Keeping this in perspective, we recommend a BUY rating on the stock with a TP of Rs 1,570/share.
Number of FII/FPI investors decreased from 257 to 239 in Sep 2025 qtr
More from Krishna Institute of Medical Sciences Ltd.
Recommended